Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474

Science

Volumn 356, Issue 6342, 2017, Pages 1084-1087

  Van Esbroeck, Annelot C M ^a   Janssen, Antonius P A ^a   Cognetta, Armand B ^b   Ogasawara, Daisuke ^b   Shpak, Guy ^c   Van Der Kroeg, Mark ^c   Kantae, Vasudev ^d   Baggelaar, Marc P ^a   De Vrij, Femke M S ^c   Deng, Hui ^a   Allarà, Marco ^e   Fezza, Filomena ^f   Lin, Zhanmin ^c   Van Der Wel, Tom ^a   Soethoudt, Marjolein ^a   Mock, Elliot D ^a   Den Dulk, Hans ^a   Baak, Ilse L ^a   Florea, Bogdan I ^a   Hendriks, Giel ^g   De Petrocellis, Luciano ^e   Overkleeft, Herman S ^a   Hankemeier, Thomas ^d   De Zeeuw, Chris I ^c,h   Di Marzo, Vincenzo ^e   Maccarrone, Mauro ^i,j   Cravatt, Benjamin F ^b   Kushner, Steven A ^c   Van Der Stelt, Mario ^a   more..

^a LEIDEN UNIVERSITY   (Netherlands)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

^e CNR   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g Robert Boyleweg 4   (Netherlands)

^h NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

ⁱ IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^j UNIVERSITY CAMPUS BIO MEDICO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 [CYCLOHEXYL(METHYL)CARBAMOYL] 1H IMIDAZOL 4 YL]PYRIDINE 1 OXIDE; BIA 10 2639; FATTY ACID AMIDASE INHIBITOR; N (3 PYRIDAZINYL) 4 [3 (5 TRIFLUOROMETHYL 2 PYRIDINYLOXY)BENZYLIDENE] 1 PIPERIDINECARBOXAMIDE; UNCLASSIFIED DRUG; AMIDASE; AMINE OXIDE; ANALGESIC AGENT; ANXIOLYTIC AGENT; FATTY-ACID AMIDE HYDROLASE; N-PYRIDAZIN-3-YL-4-(3-((5-(TRIFLUOROMETHYL)PYRIDIN-2-YL)OXY)BENZYLIDENE)PIPERIDINE-1-CARBOXAMIDE; PYRIDAZINE DERIVATIVE; PYRIDINE DERIVATIVE; UREA;

CELLS AND CELL COMPONENTS; DRUG; ENZYME; ENZYME ACTIVITY; FATTY ACID; INHIBITOR; LIPID; METABOLISM; NERVOUS SYSTEM; NEUROLOGY; PROTEIN; SYMPTOM; TOXICITY TEST;

ACTIVITY BASED PROTEIN PROFILING; ARTICLE; BRAIN CELL; BRAIN DYSFUNCTION; CARBON NUCLEAR MAGNETIC RESONANCE; CLICK CHEMISTRY; CYCLOADDITION; ENZYME ACTIVITY; FLUOROSCOPY; HEK293T CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; MASS SPECTROMETRY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CROSS REACTION; DRUG EFFECTS; METABOLISM; NERVE CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN PROTEIN INTERACTION; TUMOR CELL LINE;

AMIDOHYDROLASES; ANALGESICS; ANTI-ANXIETY AGENTS; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE I AS TOPIC; CROSS REACTIONS; CYCLIC N-OXIDES; HUMANS; NEURONS; PROTEIN INTERACTION MAPS; PYRIDAZINES; PYRIDINES; UREA;

EID: 85020735085     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aaf7497     Document Type: Article

References (28)

1. M. Eddleston, A. F. Cohen, D. J. Webb, Br. J. Clin. Pharmacol. 81, 582-586 (2016).
2. D. Butler, E. Callaway, Nature 529, 263-264 (2016).
3. A. Kerbrat et al., N. Engl. J. Med. 375, 1717-1725 (2016).
4. B. Bégaud et al., Report by the Temporary Specialist Scientific Committee (TSSC), "FAAH (Fatty Acid Amide Hydrolase)," on the causes of the accident during a Phase 1 clinical trial, 1-28 (2016).
5. B. F. Cravatt et al., Nature 384, 83-87 (1996).
6. S. Kathuria et al., Nat. Med. 9, 76-81 (2003).
7. W. A. Devane et al., Science 258, 1946-1949 (1992).
8. J. Z. Long et al., Proc. Natl. Acad. Sci. U.S.A. 106, 20270-20275 (2009).
9. M. Van Der Stelt et al., EMBO J. 24, 3026-3037 (2005).
10. A. J. Hampson et al., J. Neurochem. 70, 671-676 (1998).
11. J. P. Huggins, T. S. Smart, S. Langman, L. Taylor, T. Young, Pain 153, 1837-1846 (2012).
12. G. L. Li et al., Br. J. Clin. Pharmacol. 73, 706-716 (2012).
13. M. J. Niphakis, B. F. Cravatt, Annu. Rev. Biochem. 83, 341-377 (2014).
14. M. P. Baggelaar et al., J. Am. Chem. Soc. 137, 8851-8857 (2015).
15. Y. Liu, M. P. Patricelli, B. F. Cravatt, Proc. Natl. Acad. Sci. U.S.A. 96, 14694-14699 (1999).
16. K. Ahn et al., J. Pharmacol. Exp. Ther. 338, 114-124 (2011).
17. L. E. Kiss et al., Patent WO 2010074588 A2 (2010).
18. V. V. Rostovtsev, L. G. Green, V. V. Fokin, K. B. Sharpless, Angew. Chem. Int. Ed. 41, 2596-2599 (2002).
19. B. R. Lanning et al., Nat. Chem. Biol. 10, 760-767 (2014).
20. G. Thomas et al., Cell Reports 5, 508-520 (2013).
21. P.-A. Chang, Y.-J. Wu, Int. J. Biochem. Cell Biol. 42, 573-575 (2010).
22. A. Patat, presentation at the Safety and Regulation in Early Clinical Drug Development Symposium, Ghent, Belgium, 2 December 2016.
23. R. J. Richardson, N. D. Hein, S. J. Wijeyesakere, J. K. Fink, G. F. Makhaeva, Chem. Biol. Interact. 203, 238-244 (2013).
24. D. J. Read, Y. Li, M. V. Chao, J. B. Cavanagh, P. Glynn, J. Neurosci. 29, 11594-11600 (2009).
25. M. Moser et al., Mech. Dev. 90, 279-282 (2000).
26. R. B. Hufnagel et al., J. Med. Genet. 52, 85-94 (2015).
27. A. K. Topaloglu et al., J. Clin. Endocrinol. Metab. 99, E2067-E2075 (2014).
28. D. Bertrand, S. Bertrand, E. Neveu, P. Fernandes, Antimicrob. Agents Chemother. 54, 5399-5402 (2010).